FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla - AP News
WEBJul 2, 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
News Release - Eli Lilly and Company
WEBJul 2, 2024 · Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of treatment with Kisunla in 12 months.
New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
WEB2 days ago · SAVAW. Eli Lilly LLY announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive ...
FDA Approves Kisunla (Donanemab) | Alzheimer's Association
WEBCHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the …
WEB3 days ago · Japan is the second major market where Kisunla has received approval. Kisunla was first approved in the United States in July 2024. INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults ...
Eli Lilly’s Alzheimer’s treatment Kisunla wins approval in Japan
WEB3 days ago · Photo: Getty Images/iStockphoto. Eli Lilly & Co. Inc. said Tuesday the Japanese regulator has approved its Kisunla treatment for adults with early symptomatic Alzheimer’s disease, including ...
Eli Lilly Gets Japan OK for Kisunla Alzheimer's Disease Drug
WEB3 days ago · By Colin Kellaher. Eli Lilly has won Japanese regulatory approval for Kisunla, marking the second major market where the new Alzheimer's disease drug has received a green light. Eli Lilly on ...
Alzhiemer's drug Kisunla from Eli Lilly gains FDA approval - USA TODAY
WEBJul 2, 2024 · Eli Lilly said donanemab will be marketed under the brand name Kisunla as a monthly injection, which will be administered via IV infusion. The Alzheimer's treatment will be available for adults...
FDA approves treatment for adults with Alzheimer’s disease
WEBJul 2, 2024 · The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild...
Skip to content